↓ Skip to main content

A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood

Overview of attention for article published in BMC Research Notes, June 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
11 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood
Published in
BMC Research Notes, June 2015
DOI 10.1186/s13104-015-1255-0
Pubmed ID
Authors

Marinus J Dekkers, Jaap W Groothoff, Robert Zietse, Michiel G H Betjes

Abstract

The treatment of immune suppression dependent minimal change nephropathy (MCN) can be challenging and frequently leads to serious complications. In paediatric patients, successful treatment with rituximab is described in steroid-dependent MCN. There is limited information about the potential efficacy of rituximab for the treatment of MCN in adults and adolescence. We describe our experience with rituximab in adolescent and adult patients with immune suppression dependent MCN. Ten adolescents and adults with immune suppression dependent MCN and therapy related complications were treated with rituximab. At a mean age of 26 years, about 10.5 years after first presentation, they received two doses of rituximab (375 mg/m(2)). Maintenance immunosuppressive medication was stopped. After a mean follow-up of 43 months, three patients had four relapses. Three relapses were successfully retreated with rituximab again, after induction therapy with 60 mg prednisone per day. Rituximab was well tolerated and no infectious complications were recorded. Treatment with rituximab induces a long-term remission of immune suppression dependent MCN in adolescents and adults. A timely treatment with rituximab could be considered to limit side effects of immunosuppressive medication.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 36%
Student > Bachelor 3 27%
Student > Doctoral Student 1 9%
Librarian 1 9%
Student > Master 1 9%
Other 1 9%
Readers by discipline Count As %
Medicine and Dentistry 6 55%
Nursing and Health Professions 1 9%
Biochemistry, Genetics and Molecular Biology 1 9%
Computer Science 1 9%
Engineering 1 9%
Other 0 0%
Unknown 1 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 February 2016.
All research outputs
#5,998,029
of 8,295,152 outputs
Outputs from BMC Research Notes
#1,321
of 2,074 outputs
Outputs of similar age
#187,959
of 290,309 outputs
Outputs of similar age from BMC Research Notes
#77
of 117 outputs
Altmetric has tracked 8,295,152 research outputs across all sources so far. This one is in the 24th percentile – i.e., 24% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,074 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,309 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 117 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.